Barclays cuts Alignment Healthcare price target to $9 from $10
According to TradingView, Barclays kept Alignment Healthcare at Equal-Weight and cut its price target 10%, to $9 from $10, against an $8.06 close.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Barclays kept its Equal-Weight rating on Alignment Healthcare but reduced its price target from $10 to $9, a 10% cut. The update was reported by TradingView.
The article notes that the new target implies an 11.7% gain from the October 29 closing price of $8.06.
Over the past 30 days, the five most recent analyst notes on the company set targets between $9 and $12. They include a downgrade from KeyBanc, a neutral view from UBS at $9, and a Buy rating from TD Cowen at $12.
why it matters
Target adjustments like this rarely move the broader market on their own, but they show that banks are revising their expectations for the company. The spread of targets from $9 to $12 suggests that the stock's valuation remains uncertain.
tags
instruments
sources
- Barclays maintains Alignment Healthcare at Equal-Weight, lowers price target to $9 from $10 — TradingView, 30 October 2026 at 13:34 UTC
- Barclays maintains Ambev at Equal-Weight, lowers price target to $3 from $3.50 — TradingView, 30 October 2026 at 13:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗